Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 114,633	$ 144,761
Accounts receivable, net	81,294	80,142
Inventories, net	99,322	94,491
Prepaid clinical development costs	504	586
Prepaid Inventory Costs	18,210	13,863
Other prepaid and current assets	4,815	4,155
Total current assets	318,778	337,998
Property and equipment, net	228	254
Right of use operating lease assets	4,967	5,513
Intangible assets	56	56
Total assets	324,029	343,821
Current liabilities:
Accounts payable	71,994	51,650
Convertible notes, net of issuance costs	54,670	54,575
Accrued clinical development costs	7,071	5,035
Accrued variable consideration	56,005	56,535
Other accrued liabilities	16,625	19,593
Royalty sale liability	57,237	47,586
Deferred revenue from collaborations	4,542	8,518
Operating lease liabilities	2,822	2,741
Total current liabilities	270,966	246,233
Convertible notes, net of issuance costs	96,871	96,745
Royalty sale liability	238,982	246,024
Long-term debt	141,449	140,971
Operating lease liabilities	1,972	2,570
Total liabilities	750,240	732,543
Commitments and contingencies (Note 5)
Stockholders’ deficit:
Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of March 31, 2025 and December 31, 2024	0	0
Common stock, $0.001 par value; 480,000,000 shares authorized as of March 31, 2025 and 480,000,000 shares authorized as of December 31, 2024; 198,654,569 shares issued at March 31, 2025 and 197,846,661 shares issued at December 31, 2024	197	196
Additional paid-in capital	1,270,074	1,267,109
Treasury stock, at cost; 1,994,198 shares at March 31, 2025 and December 31, 2024	(54,998)	(54,998)
Accumulated deficit	(1,641,484)	(1,601,029)
Total stockholders’ deficit	(426,211)	(388,722)
Total liabilities and stockholders’ deficit	$ 324,029	$ 343,821